SuPAR, a Circulating Kidney Disease Factor

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2021 Oct 25

PMID 34692736

Citations 5

Authors

Changli Wei

Ryan Spear

Eunsil Hahm

Jochen Reiser

Affiliations

Soon will be listed here.

Abstract

Urokinase plasminogen activator receptor (uPAR) is a multifaceted, GPI-anchored three-domain protein. Release of the receptor results in variable levels of soluble uPAR (suPAR) in the blood circulation. suPAR levels have been linked to many disease states. In this mini-review, we discuss suPAR as a key circulating molecule mediating kidney disease with a particular focus on differently spliced isoforms.

Citing Articles

Pathogenesis of Focal Segmental Glomerulosclerosis and Related Disorders.

Altintas M, Agarwal S, Sudhini Y, Zhu K, Wei C, Reiser J Annu Rev Pathol. 2025; 20(1):329-353.

PMID: 39854184 PMC: 11875227. DOI: 10.1146/annurev-pathol-051220-092001.

Biomarkers of chronic kidney disease in older individuals: navigating complexity in diagnosis.

Muglia L, Di Dio M, Filicetti E, Greco G, Volpentesta M, Beccacece A Front Med (Lausanne). 2024; 11:1397160.

PMID: 39055699 PMC: 11269154. DOI: 10.3389/fmed.2024.1397160.

Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator.

Hamada M, Varkoly K, Riyadh O, Beladi R, Munuswamy-Ramanujam G, Rawls A Biomedicines. 2024; 12(6).

PMID: 38927374 PMC: 11201033. DOI: 10.3390/biomedicines12061167.

suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury.

Nusshag C, Wei C, Hahm E, Hayek S, Li J, Samelko B JCI Insight. 2023; 8(7).

PMID: 37036003 PMC: 10132159. DOI: 10.1172/jci.insight.165740.

Ion channels and channelopathies in glomeruli.

Staruschenko A, Ma R, Palygin O, Dryer S Physiol Rev. 2022; 103(1):787-854.

PMID: 36007181 PMC: 9662803. DOI: 10.1152/physrev.00013.2022.

References

Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner K . The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 1998; 420(1):79-85. DOI: 10.1016/s0014-5793(97)01491-9. View

Gardsvoll H, Ploug M . Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J Biol Chem. 2007; 282(18):13561-72. DOI: 10.1074/jbc.M610184200. View

Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Dano K . The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem. 1991; 266(12):7842-7. View

Smith H, Marshall C . Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2009; 11(1):23-36. DOI: 10.1038/nrm2821. View

Morath C, Wei C, Macher-Goeppinger S, Schwenger V, Zeier M, Reiser J . Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification. Am J Ther. 2013; 20(2):226-9. DOI: 10.1097/MJT.0b013e3182811aca. View

Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F . A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1998; 16(24):7279-86. PMC: 1170328. DOI: 10.1093/emboj/16.24.7279. View

Almus-Jacobs F, Varki N, Sawdey M, Loskutoff D . Endotoxin stimulates expression of the murine urokinase receptor gene in vivo. Am J Pathol. 1995; 147(3):688-98. PMC: 1870967. View

Alachkar N, Wei C, Arend L, Jackson A, Racusen L, Fornoni A . Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation. 2013; 96(7):649-56. PMC: 4026282. DOI: 10.1097/TP.0b013e31829eda4f. View

Schenk H, Muller-Deile J, Schmitt R, Brasen J, Haller H, Schiffer M . Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb. J Clin Apher. 2017; 32(6):444-452. DOI: 10.1002/jca.21538. View

10.

Blasi F, Carmeliet P . uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002; 3(12):932-43. DOI: 10.1038/nrm977. View

11.

Behrendt N, Ronne E, Dano K . Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem. 1996; 271(37):22885-94. DOI: 10.1074/jbc.271.37.22885. View

12.

Huai Q, Zhou A, Lin L, Mazar A, Parry G, Callahan J . Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol. 2008; 15(4):422-3. PMC: 2443823. DOI: 10.1038/nsmb.1404. View

13.

Dowsett J, Ferkingstad E, Hartmann Rasmussen L, Thorner L, Magnusson M, Sugden K . Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor. Commun Biol. 2021; 4(1):655. PMC: 8172928. DOI: 10.1038/s42003-021-02144-8. View

14.

Tang W, Friess H, di Mola F, Schilling M, Maurer C, Graber H . Activation of the serine proteinase system in chronic kidney rejection. Transplantation. 1998; 65(12):1628-34. DOI: 10.1097/00007890-199806270-00015. View

15.

Charba D, Wiggins R, Goyal M, Wharram B, Wiggins J, McCarthy E . Antibodies to protein tyrosine phosphatase receptor type O (PTPro) increase glomerular albumin permeability (P(alb)). Am J Physiol Renal Physiol. 2009; 297(1):F138-44. PMC: 2711708. DOI: 10.1152/ajprenal.00122.2008. View

16.

Sidenius N, Andolfo A, Fesce R, Blasi F . Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J Biol Chem. 2002; 277(31):27982-90. DOI: 10.1074/jbc.M111736200. View

17.

Kopp J, Heymann J . c-Src is in the effector pathway linking uPAR and podocyte injury. J Clin Invest. 2019; 129(5):1827-1829. PMC: 6486326. DOI: 10.1172/JCI127927. View

18.

Savin V, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R . Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family. J Immunol Res. 2015; 2015:714964. PMC: 4471311. DOI: 10.1155/2015/714964. View

19.

Sidenius N, Sier C, Blasi F . Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 2000; 475(1):52-6. DOI: 10.1016/s0014-5793(00)01624-0. View

20.

Xu Y, Hagege J, Mougenot B, Sraer J, Ronne E, Rondeau E . Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Kidney Int. 1996; 50(6):2011-9. DOI: 10.1038/ki.1996.523. View